Mabpharm-B (02335.HK) Receives First Project Funding Under National Science and Technology Major Project and Obtains Ethics Approval from Lead Site for Phase III Clinical Trial of MT200605

Zhitong Finance APP news, Maike Medicine-B (02335.HK) announced that the Company and Beijing Tiantan Hospital, Capital Medical University (Beijing Tiantan Hospital) jointly undertake a research project under the National Science and Technology Major Project "Major New Drug Creation" involving the Company's key product MT200605, and have recently received the first central government special funding for this project. The Company has also obtained ethics approval from the lead unit for the Phase III clinical trial of MT200605.